McCarthy Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

McCarthy Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25	Closed	-$2K	–	71
2022 Q1	$2K	Hold	25	–	–	﹤0.01%	274
2021 Q4	$2K	Hold	25	–	–	﹤0.01%	271
2021 Q3	$2K	Hold	25	–	–	﹤0.01%	268
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	324
2021 Q1	$2K	Buy	+25	New	+$2.04K	﹤0.01%	283

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

McCarthy Asset Management's BMRN Position: Q2 2022 in Review

McCarthy Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 25 shares — an estimated $2K sold.

McCarthy Asset Management first reported a position in BMRN in Q1 2021 and held it in 5 quarters. The position peaked at $2K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

McCarthy Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 25 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $2K.
McCarthy Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 5 quarters.
McCarthy Asset Management's BioMarin Pharmaceuticals position peaked at $2K in Q1 2022.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.